NCCN Tumor Boards: Advances in the Management of Early-Stage and Locally Advanced Cervical Cancer

January 14, 2027
The standard treatment options for cervical cancer have remained surgical intervention for early-stage disease and concurrent chemoradiation for locally advanced disease for more than twenty years. With the recent phase III trials supporting treatment de-escalation strategies, sentinel lymph node-based staging, fertility-sparing approaches, and induction chemotherapy, new treatment paradigms have emerged changing the treatment landscape for early-stage disease and providing additional options for locally advanced cervical cancer.
 
Clinicians are challenged to remain up to date about advances in management of cervical cancer. These practice-changing approaches need to be continuously integrated into clinical practice which will likely improve survival rates, reduce recurrence and improve quality of life for cervical cancer patients.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, physician assistants/associates, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

Following this activity, participants should be able to:

  • Discuss pivotal clinical trials that have reshaped the management of low-risk, early-stage cervical cancer in recent years.
  • Elaborate on the key differences in patient selection for GOG-0278, ConCerv, and SHAPE trials, and how they impact treatment strategies and disease management of early-stage cervical cancer.
  • Evaluate INTERLACE trial data and discuss the potential benefits, risks and global considerations associated with adopting this treatment strategy for locally advanced cervical cancer. 

You may also be interested in

Recorded Presentation of NCCN Optimizing Patient Outcomes - Recent Advancements in Chemoradiation Strategies for Locally Advanced Cervical Cancer

Recent trials have reported advances of chemoradiation strategies in the treatment of locally advanced cervical cancer, which have been incorporated into the NCCN Guidelines®.
Additional information
Supporters: 
This activity is supported by educational grants from:
  • AstraZeneca
  • Johnson & Johnson
  • Lilly
  • Novartis
  • Nuvalent, Inc. 
Supported by an education grant from Nuvation Bio. 
 
This activity is supported by independent educational grants from:
  • Merck & Co., Inc., Rahway, NJ, USA.
  • Regeneron Pharmaceuticals, Inc. 

Course summary

Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Course opens: 
10/21/2026
Course expires: 
04/04/2027
Event starts: 
01/14/2027 - 1:00pm EST
Event ends: 
01/14/2027 - 2:00pm EST
Part of: 
NCCN Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care
Add to calendar: 
Presenters
Nadeem R. Abu-Rustum, MD
Kay Park, MD
Maria M. Rubinstein, MD
Memorial Sloan Kettering Cancer Center
 
NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Full disclosure of faculty relationships will be made prior to the activity. 

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.
 
Pharmacists
NCCN designates this knowledge-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit.
 
UAN: TBD
 
Physician Associates
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.
 
Case Managers
This program has been pre-approved by The Commission to provide continuing education credit to CCM® Board-Certified Case Managers. The course is approved for 1.0 CE contact hour.
 
Activity Code: Pending; Approval Number: Pending
 
To claim these CEs, log into your dashboard at www.yourcommission.org.  

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 CCM clock hours
  • 1.00 Participation
Please login or register to take this course.

Click the Take Course button to register for the live webinar.

  • The webinar will be presented live one time only on Thursday, January 14, 2027, at 1:00 – 2:00 PM [EST (UTC -5)].
  • To adjust for other time zones, click here.

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, you will need: 

  • A device with an Internet connection and sound playback capability (speakers or a headset) 
  • Adobe Reader or other PDF reader software for certificate viewing/printing